Xeris Biopharma Holdings Inc. Stock
Heavy losses for Xeris Biopharma Holdings Inc. today as the stock fell by -€0.556 (-7.910%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a positive potential of 23.65% compared to the current price of 6.47 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | -7.910% | -2.983% | -1.981% | 46.010% | 11.259% | 187.951% | 235.851% |
| Evolus Inc | 2.620% | -0.077% | -12.697% | -31.421% | -4.367% | -41.438% | -40.434% |
| Heron Therapeutics Inc. | -1.120% | 1.641% | 16.685% | -72.205% | -61.077% | -71.285% | -95.688% |
| Rhythm Pharmaceuticals | -1.050% | -2.162% | -8.122% | 20.667% | -3.209% | 315.138% | 666.949% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat